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ATL carries a very bad prognosis because of intrinsic
chemoresistance and severe immuno-suppression. In
acute ATL, chemotherapy combinations improved
response rate but failed to achieve a significant impact
on survival. Patients with chronic and smoldering ATL
have a better prognosis but long-term survival is poor
when patients are managed with a watchful-waiting pol-
icy or with chemotherapy. The antiviral combination of
zidovudine (AZT) and interferon-alpha (IFN) improves
survival in leukemic subtypes of ATL (smoldering and
chronic ATL and acute ATL with wild type p53) and
should be considered as standard first line therapy.
However, it is mandatory to 1) use it in leukemic forms
as first line therapy and not after one or more cycles of
chemotherapy; 2) start with high doses of both agents
since reduced doses are often not effective. ATL lym-
phoma may benefit from initial chemotherapy combined
to or followed by AZT/IFN and this approach should be
tested in prospective clinical trials. Prophylaxis of oppor-
tunistic infections and intrathecal chemotherapy are
mandatory. Yet, most patients relapse and alternative
therapies are mandatory. IFN and arsenic trioxide
induce Tax proteolysis, synergize to induce apoptosis in
ATL cells and cure Tax-driven ATL in mice through
specific targeting of leukemia initiating cell activity.
Therefore, to prevent relapse, clinical trials assessing
consolidative targeted therapies such as arsenic/IFN
combination, histone deacetylase inhibitors or novel
monoclonal antibodies particularly brentuximab in
CD30 positive cases or the promising anti CCR4 antibo-
dies, are mandatory after achieving CR with AZT/IFN.
Finally, allogeneic BMT should be considered in suitable
patients.
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